Heterologous Systemic Prime–Intranasal Boosting Using a Spore SARS-CoV-2 Vaccine Confers Mucosal Immunity and Cross-Reactive Antibodies in Mice as well as Protection in Hamsters
Katsande, Paidamoyo M.
Ferreira, William T.
Hong, Huynh A.
Cutting, Simon M.
Background: Current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are administered systemically and typically result in poor immunogenicity at the mucosa. As a result, vaccination is unable to reduce viral shedding and transmission, ultimately failing to prevent infection. One possible solution is that of boosting a systemic vaccine via the nasal route resulting in mucosal immunity. Here, we have evaluated the potential of bacterial spores as an intranasal boost. Method: Spores engineered to express SARS-CoV-2 antigens were administered as an intranasal boost following a prime with either recombinant Spike protein or the Oxford AZD1222 vaccine. Results: In mice, intranasal boosting following a prime of either Spike or vaccine produced antigen-specific sIgA at the mucosa together with the increased production of Th1 and Th2 cytokines. In a hamster model of infection, the clinical and virological outcomes resulting from a SARS-CoV-2 challenge were ameliorated. Wuhan-specific sIgA were shown to cross-react with Omicron antigens, suggesting that this strategy might offer protection against SARS-CoV-2 variants of concern. Conclusions: Despite being a genetically modified organism, the spore vaccine platform is attractive since it offers biological containment, the rapid and cost-efficient production of vaccines together with heat stability. As such, employed in a heterologous systemic prime–mucosal boost regimen, spore vaccines might have utility for current and future emerging diseases.
619 - Veterinària
Is part of
Katsande, Paidamoyo M., Leira Fernández-Bastit, William T. Ferreira, Júlia Vergara-Alert, Mateusz Hess, Katie Lloyd-Jones, Huynh A. Hong, Joaquim Segales, and Simon M. Cutting. 2022. "Heterologous Systemic Prime–Intranasal Boosting Using A Spore SARS-Cov-2 Vaccine Confers Mucosal Immunity And Cross-Reactive Antibodies In Mice As Well As Protection In Hamsters". Vaccines 10 (11): 1900. doi:10.3390/vaccines10111900.
Grant agreement number
EC/H2020/730964/EU/European Vaccine Research and Development Infrastructure/TRANSVAC2
This item appears in the following Collection(s)
- ARTICLES CIENTÍFICS 
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/